Telix Pharmaceuticals' CUPID Study Demonstrates Promising Results for Next-Generation Prostate Cancer Therapy

21 May 2024 | Tuesday | News

Phase I Study of TLX592 Shows Rapid Blood Clearance and Hepatic Elimination, Paving the Way for Advanced Therapeutic Trials in Late 2024
Image Source : Public Domain

Image Source : Public Domain

  • CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.
  • Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets.
  • Initial results demonstrate rapid elimination from blood circulation compared to standard antibodies and hepatic (liver) clearance – both highly desirable characteristics for use with alpha emitting agents.
  • Successful completion of mass dose escalation study establishes a baseline dosing schedule for future studies of TLX592 using actinium-225.
  • Data is supportive of advancement to a therapeutic Phase I/II study in H2 2024.

 Telix Pharmaceuticals announces the successful completion of CUPID[1], a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.


TLX592 (225Ac-PSMA-RADmAb®) is Telix's investigational "next generation" targeted alpha therapy (TAT) for the treatment of prostate cancer and is the first clinical program to utilise Telix's proprietary RADmAb® engineered antibody technology. The RADmAb® approach accelerates blood clearance and reduces bone marrow residence time compared with standard monoclonal antibodies (mAbs), while retaining target selectivity, internalisation and retention. The RADmAb® platform is currently under pre-clinical and clinical evaluation for multiple cancer targets.

The CUPID (64Cu PSMA Imaging and (Bio) Distribution) study is a 3+3 mass dose escalation study with four patient cohorts intended to evaluate the safety, tolerability, pharmacokinetics, biodistribution and radiation dosimetry of TLX592. The study utilises copper-64 (64Cu) which is detectable by Positron Emission Tomography (PET) as a surrogate for actinium-225 (225Ac), enabling a successful proof-of-targeting study as well as predictive dosimetry calculations for future studies with 225Ac. Preliminary results in 11 evaluable patients enrolled in the study demonstrated accelerated blood kinetics compared to the standard antibody TLX591, while demonstrating similar (favourable) on-target and off-target biodistribution and hepatic clearance. There were no serious adverse events observed in the study.

Based on these encouraging results, Telix expects to advance TLX592 into a therapeutic Phase I/II study with 225Ac in the second half of 2024, subject to regulatory approval. TLX592 further deepens Telix's PSMA[2]-targeting prostate cancer therapy portfolio and supplements its lead investigational radio antibody-drug conjugate (rADC) TLX591 (177Lu rosopatamab tetraxetan), currently being investigated in the ProstACT GLOBAL Phase III study. The Company intends to publish and present non-clinical and clinical data supporting these results at several upcoming symposia.  

Dr David N. Cade, Group Chief Medical Officer at Telix stated, "The CUPID study demonstrated clearly how theranostic approaches can be used to streamline novel radiopharmaceutical drug development. In this case, PET imaging was used to dose-find a targeting agent for future use with an alpha emitter, while establishing basic safety and utility parameters that will greatly inform ongoing development of this product candidate.

"There is a significant unmet need for novel targeting platforms that may be used with alpha emitting isotopes and avoid renal toxicity and other off-target effects, such as the exocrine gland uptake typical of PSMA small molecule agents. We are excited to progress TLX592 into therapeutic studies where our aim is to develop this agent for both early metastatic prostate cancer and late-stage patients who are no longer responding to lutetium therapy. We would like to thank all participants for their commitment to the CUPID study."


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in